Skip to content

RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy

Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00127582
Enrollment
537
Registered
2005-08-08
Start date
2003-01-01
Completion date
2010-12-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic Dystrophy, Sudden Cardiac Death

Keywords

Myotonic dystrophy type 1, Sudden cardiac death, Ventricular tachyarrhythmias, Bradyarrhythmias

Brief summary

This is a prospective multicentric Italian study to evaluate the arrhythmic risk in myotonic dystrophy type 1.

Detailed description

Myotonic dystrophy type 1 (DM1, Steinert disease) is a multisystem disorder that affects, beside muscle, several other organs, including the heart. Cardiac involvement represents a major problem in the clinical management of patients, so that cardiac complications represent one of the primary causes of premature death in DM1. In particular there is a high incidence of sudden death, ranging from 2 to 30% of cases, so far principally related to the development of conduction blocks. However, literature reports of sudden death in patients implanted with pacemakers, as well as of spontaneous ventricular tachycardia would suggest a potential etiologic role also for ventricular arrhythmias. The lack of clinical research studies conducted on a large number of patients does not make available definite data regarding the etiology and the epidemiology of arrhythmic events in DM1. For the same reasons, other considerable topics, such as prognostic stratification of the arrhythmic risk and clinical management of life-threatening arrhythmias in DM1 patients, are still undefined. To clarify these issues, the investigators propose a clinical research study performed on a large cohort of DM1 patients enrolled through a multicenter collaboration that also involves 5 cardiological-neurological Italian centres. Aims of this study are: * To estimate the incidence of arrhythmias and to characterize the brady-tachyarrhythmic mechanisms underlying the occurrence of cardiac sudden death in DM1; * To verify by statistical analysis the reliability of data obtained from both non invasive and invasive diagnostic procedures as indexes useful for estimating the arrhythmic risk in DM1; * To identify more adequate therapeutic guidelines in order to prevent the occurrence of life-threatening arrhythmias. The protocol of study includes: 1. Clinical-genetic evaluation; 2. Non invasive and invasive diagnostic cardiac procedures; 3. The use of devices for diagnostic and therapeutic follow-up.

Interventions

DEVICEpacemaker , implantable cardiac defibrillator or loop-recorder implant

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patient affected by myotonic dystrophy type I (MD1). * Patient willing to provide a signed informed consent.

Exclusion criteria

* Age \< 18 years old or \>70 years old. * Ischemic cardiomyopathy * Cardiomyopathy due to chronic excess of alcohol consumption (\>100 g\\day) * Congenital heart disease * Acquired valvular heart disease * Metabolic cardiomyopathy: thyrotoxicosis, hypothyroidism, adrenal cortical insufficiency, pheochromocytoma, acromegaly * Familiar storage and infiltrative diseases (hemochromatosis, glycogen storage, Hurler's syndrome, Niemann-Pick disease; primary, secondary, familial and hereditary cardiac amyloidoses) * Systemic diseases (connective tissue disorder; sarcoidosis) * Peripartum cardiomyopathy

Design outcomes

Primary

MeasureTime frameDescription
Incidence of major cardiac events (sudden death)2 yearsTo assess the 2-year cumulative incidence of sudden death in patients affected by Myotonic dystrophy type 1.
Resuscitated cardiac arrest2 yearsTo evaluate the value of noninvasive and invasive findings as predictive factors for resuscitated cardiac arrest.

Countries

Italy

Contacts

PRINCIPAL_INVESTIGATORFulvio Bellocci, MD

Catholic University of Sacred Heart

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026